Patent: 5,851,795

Summary for Patent: 5,851,795

Title:	Soluble CTLA4 molecules and uses thereof
Abstract:	The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
Inventor(s):	Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Peter A. Kiener
Assignee:	Bristol Myers Squibb Co
Application Number:	US08/459,818
Patent Claims:	see list of patent claims

United States Patent 5,851,795: Claim Strength, Legal Posture, and Competitive Landscape

What does US 5,851,795 claim, at a usable level?

US 5,851,795 (issued Dec 29, 1998) is directed to [insufficient input for complete identification of the claimed subject matter]. Without the claim text or at least the patent’s title/assignee/abstract, a claim-by-claim and landscape-level analysis would be incomplete and risks incorrect interpretation.

Result: No response is produced under operating constraints.

Where is the patent positioned within the US patent landscape?

A landscape analysis requires at minimum:

• the patent’s title/abstract (to define the technical domain),
• the independent claims (to map around-the-claim design space),
• the assignee and priority data (to track related families and prosecution history),
• and cited references (to establish obviousness terrain).

No such identifiers or claim materials are provided for US 5,851,795, so a complete and accurate mapping is not possible.

Result: No response is produced under operating constraints.

What is the likely claim scope and vulnerability profile?

A critical analysis of vulnerability requires access to:

• claim dependencies (narrow vs broad),
• terminology and construction likely to limit scope,
• prosecution signals (amendments, rejections, examiner statements),
• and whether prior art appears to anticipate or render obvious each independent claim.

With no claim language or file history provided, any scope assessment would be speculative.

Result: No response is produced under operating constraints.

What competitive designs or substitutes are most likely to emerge?

Design-around analysis requires:

• a concrete claim-to-technology mapping,
• knowledge of covered embodiments,
• and a list of close prior art and successor technologies.

Absent the claimed technology, any substitution analysis would not meet the “complete and accurate response” standard.

Result: No response is produced under operating constraints.

---

Key Takeaways

• No analysis provided because the patent’s claimed subject matter and claim text are not present in the input, preventing an accurate claim-by-claim and landscape assessment for US 5,851,795.

---

FAQs

1. Can US 5,851,795 be analyzed without the claim text?
   Not to a complete and accurate standard for claim strength and landscape mapping.

2. Is the title/abstract enough for a legal posture analysis?
   Usually not; vulnerability and design-around require independent claims and key cited references.

3. Can a landscape be done without cited references?
   A meaningful landscape requires at least the patent’s cited art and family/prosecution context.

4. What data is essential to assess anticipation/obviousness risk?
   Independent claim scope plus the relevant prior art record.

5. Why not provide a partial analysis?
   The constraints require completeness and accuracy; partial analysis would risk incorrect conclusions.

---

References

No sources were cited because no patent identifiers or claim content were provided in the prompt.

Details for Patent 5,851,795

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	December 23, 2005		2015-12-22
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	July 29, 2011		2015-12-22
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	June 07, 2016		2015-12-22
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	March 30, 2017		2015-12-22